Glycoprotein Ia gene C807T polymorphism and risk for major adverse cardiac events within the first 30 days after coronary artery stenting

Blood

Volumn 95, Issue 11, 2000, Pages 3297-3301

  Von Beckerath, Nicolas ^a   Koch, Werner ^a   Mehilli, Julinda ^a   Böttiger, Corinna ^a   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CREATINE KINASE MB; DNA; HEART ENZYME; TICLOPIDINE; VERY LATE ACTIVATION ANTIGEN 2;

ADULT; AGED; ALLELE; ANGINA PECTORIS; ANGIOGRAPHY; ANGIOPLASTY; ARTICLE; BRAIN INFARCTION; CORONARY ARTERY; CORONARY STENT; FEMALE; GENE; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOSIS;

EID: 0034210656     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.11.3297     Document Type: Article

References (46)

1. Verkleij MW, Morton LF, Knight CG, de Groot PG, Barnes MJ, Sixma JJ. Simple collagen-like peptides support platelet adhesion under static but not under flow conditions: interaction via alpha2 beta1 and von Willebrand factor with specific sequences in native collagen is a requirement to resist shear forces. Blood. 1998;91:3808.
2. Santoro SA. Platelet surface collagen receptor polymorphisms: variable receptor expression and thrombotic/hemorrhagic risk. Blood. 1999;93: 3575.
3. Nieuwenhuis HK, Akkerman JW, Houdijk WP, Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature. 1985;318:470.
4. Kehrel B, Balleisen L, Kokott R, et al. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood. 1988;71:1074.
5. Handa M, Watanabe K, Kawai Y, et al. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost. 1995;73:521.
6. Deckmyn H, Chew SL, Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemost. 1990;64:74.
7. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin alpha 2 beta 1 activity on human platelets. Blood. 1993;82:2693.
8. Corral J, Rivera J, Gonzalez-Conejero R, Vicente V. The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. Transfusion. 1999;39:372.
9. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood. 1997;89:1939.
10. Santoso S, Kalb R, Walka M, Kiefel V, Mueller-Eckhardt C, Newman PJ. The human platelet alloantigens Br(a) and Br(b) are associated with a single amino acid polymorphism on glycoprotein Ia (integrin subunit α2). J Clin Invest. 1993;92: 2427.
11. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood. 1998;92:2382.
12. Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function: effect in thromboembolic diseases. Thromb Haemost. 1999;81:951.
13. Moshfegh K, Wuillemin WA, Redondo M, et al. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet. 1999;353:351.
14. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood. 1999;93:2449.
15. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood. 1999;93:3583.
16. Croft SA, Hampton KK, Sorrell JA, et al. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction [in process citation]. Br J Haematol. 1999;106:771.
17. Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316:701.
18. Schomig A, Kastrati A, Mudra H, et al. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation. 1994;90:2716.
19. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331: 489.
20. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496.
21. Schuhlen H, Kastrati A, Dirschinger J, et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 1998;98:104.
22. Gawaz M, Neumann FJ, Ott I, May A, Rudiger S, Schomig A: Changes in membrane glycoproteins of circulating platelets after coronary stent implantation. Heart. 1996;76:166.
23. Sheth S, Litvack F, Dev V, Fishbein MC, Forrester JS, Eigler N. Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. Circulation. 1996;94:1733.
24. Rogers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 1995;91:2995.
25. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 1996;334:1084.
26. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal. 1999;14:143.
27. Kalb R, Santoso S, Unkelbach K, Kiefel V, Mueller-Eckhardt C. Localization of the Br polymorphism on a 144 bp exon of the GPIa gene and its application in platelet DNA typing. Thromb Haemost. 1994;71:651.
28. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990;82:1193.
29. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med. 1985; 312:932.
30. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992;48:361.
31. Abdelmeguid AE, Ellis SG, Sapp SK, Whitlow PL, Topol EJ. Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. Am Heart J. 1996;131: 1097.
32. Kiefel V, Santoso S, Katzmann B, Mueller-Eckhardt C. The Bra/Brb alloantigen system on human platelets. Blood. 1989;73:2219.
33. Holensteiner A, Walchshofer S, Adler A, Kittl EM, Mayr WR, Panzer S. Human platelet antigen gene frequencies in the Austrian population. Haemostasis. 1995;25:133.
34. A), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol. 1995;89: 169.
35. Di Paola J, Federici AB, Mannucci PM, et al. Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood. 1999;93:3578.
36. Neumann FJ, Gawaz M, Ott I, May A, Mossmer G, Schomig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol. 1996;27:15.
37. Gutensohn K, Beythien C, Bau J, Meinertz T, Kuehnl P. Flow cytometric analysis of coronary stent-induced alterations of platelet antigens in an in vitro model. Thromb Res. 1997;86:49.
38. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87.
39. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation. 1999;99:E1.
40. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med. 1997;336:1276.
41. Gutstein DE, Fuster V. Pathophysiology and clinical significance of atherosclerotic plaque rupture. Cardiovasc Res. 1999;41:323.
42. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657.
43. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation. 1997;95:594.
44. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation. 1999;99:1780.
45. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126.
46. Beythien C, Gutensohn K, Bau J, et al. Influence of stent length and heparin coating on platelet activation: a flow cytometric analysis in a pulsed floating model. Thromb Res. 1999;94:79.